Tyson Harris, NP
Adult Health · Blackfoot, IDNPI 1588905699
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,555 of the $8,074 with a category attached, or 81.2%. It is spread thinly across 35 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Enterra Medical, Inc.$2K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$433
- Bristol Myers Squibb$382
- Pfizer$362
- plus $2K from 29 others
What the payments were for
- Travel & lodging$1,41918%
- Food & beverage$6,55581%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 138 | $1,878 |
| Enterra Medical, Inc. | 7 | $1,730 |
| AbbVie | 63 | $1,216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $433 |
| Bristol Myers Squibb | 27 | $382 |
| Pfizer | 25 | $362 |
| Johnson & Johnson | 11 | $337 |
| Phathom Pharmaceuticals, Inc. | 11 | $190 |
| Regeneron Healthcare Solutions, Inc. | 8 | $186 |
| Gilead | 7 | $148 |
| Ardelyx, Inc. | 6 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $97 |
| Novartis | 5 | $91 |
| QOL Medical, LLC | 4 | $87 |
| Sanofi | 5 | $84 |
| Ipsen Biopharmaceuticals, Inc | 3 | $80 |
| Aimmune Therapeutics, Inc. | 4 | $71 |
| Madrigal Pharmaceuticals | 4 | $66 |
| Intercept Pharmaceuticals, Inc. | 3 | $63 |
| Braintree Laboratories, Inc. | 3 | $57 |
| Ferring Pharmaceuticals Inc. | 3 | $53 |
| Nestle Healthcare Nutrition Inc. | 2 | $49 |
| Echosens North America, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| EMD Serono, Inc. | 2 | $32 |
| Redhill Biopharma Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Merck | 1 | $21 |
| Amgen | 1 | $21 |
| Abbott | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Convatec Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Novo Nordisk | 1 | $14 |
How this compares
$8,074 in reported general payments places this provider in the 90th percentile of 38 adult health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 14 | $104,417 |
| LinzessLinaclotide | 61 | $34,896 |
| Budesonide DrBudesonide | 22 | $14,366 |
| Ursodiol | 25 | $7,836 |
| MotegrityPrucalopride Succinate | 14 | $7,366 |
| Dexlansoprazole DrDexlansoprazole | 16 | $1,825 |
| Famotidine | 157 | $1,552 |
| Omeprazole | 230 | $1,527 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 20 | $1,275 |
| Pantoprazole Sodium | 98 | $1,098 |
| Sucralfate | 26 | $1,081 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 29 | $971 |
| Esomeprazole Magnesium | 30 | $620 |
| Promethazine Hcl | 17 | $482 |
| Spironolactone | 20 | $405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,216 | $34,89661 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $433 | $7,36614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 38 adult health providers in Idaho.
Other adult health in Blackfoot
- Michelle HicksBoise$40K
- Alisa OrrIdaho Falls$10K
- Kaitlin HawsBoise$7K
- Jonelle HudsonBoise$6K
- Nicole BartlettTwin Falls$3K
- Leslie HassTwin Falls$2K
- Alla OsipchukCaldwell$2K
- Gregory MoranBoise$2K
- Vanessa SchultzNampa$2K
- Holly HamnerNampa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.